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Graft failure is a highly unsatisfactory outcome of allo-
geneic transplant. Several factors have been identiﬁed which
may predict for graft failure, however factors inﬂuencing the
success of a second allogeneic transplant in this setting are
not well studied.
Methods: The BSBMT analysed 130 patients receiving
a second allogeneic transplant for graft failure. Patients were
identiﬁed from the BSBMT Data Registry and transplant
centres were approached to provide follow up data.
Results: The median age of patients was 9 (range 4m-69),
with 53 (40%) being adults (>18). The disease was malignant
(47%) or non-malignant (53%). The majority of patients had
conditioning for the second transplant (68%), which included
serotherapy (Alemtuzumab/ATG) in almost all cases. This
was myeloablative (30%) or reduced intensity (39%)
(compared to 56% and 43%, respectively, at ﬁrst transplant).
The donor was a sibling (24%), unrelated donor (58%) or
other relative (18%). In 74% the same donor was used. The
stem cell source was bone marrow (41%), PBSC (54%), both
(2%) and UCB (3%) (compared to 53%, 38%, 1% and 7%,
respectively, at ﬁrst transplant). Stable engraftment occurred
in 88% of patients following the second transplant. Factors
associated with a signiﬁcant increase in engraftment failure
were older age (p¼0.003), male recipients (p¼0.025),
reduced intensity conditioning (compared to myeloablative
or none) (p¼0.031), the use of a different donor (p¼0.026)
and transplant for a malignant diagnosis (p¼0.005). Age
(HR¼11.52, p¼0.001) and the use of a different donor
(HR¼8.17, p¼0.003) remained signiﬁcant in the multivariate
analysis. The donor type, stem cell source and the time post
ﬁrst transplant did not impact on engraftment. Overall
survival was 60% at 5 years in the entire group. OS was
signiﬁcantly worse in adult patients (37% vs 74%, p<0.0001),
those with malignant disease (40% vs 78%, p¼0.0001) and
those transplanted beyond 3months after the ﬁrst transplant
(47% vs 65%, p¼0.02). No other factors tested were signiﬁ-
cant, and only malignancy remained signiﬁcantly associated
with OS in multivariate analysis (HR¼2.53, p¼0.018).
Conclusion: These encouraging results suggest that
successful engraftment and long term survival is possible
following a second transplant for graft failure. Although
outcomes are superior in children and those with non-
malignant disease, over a third of adult patients and those
with malignant diseases can also achieve long term survival.25
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The conﬁrmatory typing (CT) stage of unrelated donor
acquisition is a key source of delays to haematopoietic cell
provision. Identifying factors that might predict donor
deferral at this stage is important in reducing this delay and
improving patient outcome.
Methods: All CT requests made from Anthony Nolan
between 2010-11 were reviewed, and reason for deferral and
donor characteristics documented. Associations were deter-
mined using multivariate logistic regression analysis.Results: Of 7542 requests, 56.3% were completed, 38.2%
cancelled for donor reasons and 5.5% cancelled for transplant
centre reasons. Of donor cancellations 19.4% were personal,
34.1% medical, 36% no contact made, 7.9% overseas/
emigrated and 2.6% other. When compared to UK/North
European donors, African (OR 2.56, p¼0.001), Afro-Carib-
bean (OR 2.13, p<0.001), Asian (OR 2.45, p<0.001) and
Mediterranean donors (OR 1.93, p¼0.005) were more likely
to defer for donor reasons. Female donors were more likely
to defer for donor reasons (OR 1.19, p¼0.001), even when
pregnancy was excluded. This may be partly explained by
more medical deferrals (54% vs 46%). Donor age was also
associated with deferral, with more deferred aged 31-45 (OR
1.20, p¼0.002) and 46-60 (OR 1.43, p<0.001), compared to
18-30. This difference is largely explained by higher rates of
medical deferral (20.9% vs 34.6% vs 45.8% of all donor
cancellations for donors aged 18-30, 31-45 and 46-60
respectively), despite older donors being more easily con-
tacted, with fewer personal deferrals. Of medical deferrals,
19.4% of donors were deferred for morbid obesity (BMI>35),
14.4% for malignancy, 11.1% autoimmune conditions, 10.6%
cardiac, 5.3% back complaints and 7.1% diabetes. Blood
donors were less likely to be deferred for donor reasons (OR
0.72, p<0.001).
Conclusion: Despite over 20 million unrelated donors listed
on registers worldwide, high rates of donor attrition
considerably attenuate this resource and have a signiﬁcant
impact on donor provision. Donors from some ethnic
minorities have a particularly high rate of attrition. As
a registry, we are employing a number of strategies to
address the results of this study: increasing the base of
younger donors by reducing the joining age to 16-30, donor
pre-activation, use of social media to maintain contact with
donors and in depth interviews with those donors who
choose not to proceed.26
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Background: Allogeneic transplantation of haemopoietic
stem cells (HCT) from an HLA-matched related (MRD) or
unrelated donor (MUD) is a curative option for patients (pts)
affected by high-risk hematological diseases (HRHD). The
trend of growth of HCTs in adult pts with HRHD can be ex-
pected to continue based on acceptance and availability of
alternative donor. Few data are available for: i) the reliable
estimates of the number of HCT and the total number of pts
